Sign inJoin waitlistJoin the waitlist

Ayman Qasrawi

Associate Program Director · University of Kentucky College of Medicine

Credentials: · · · · · ·

History

University of Kentucky College of Medicine
Present
University of Kentucky College of Medicine
Present

Hematology and Medical Oncology
University of Kentucky College of Medicine
2018–2021
Internal Medicine
2015–2018
Doctor of Medicine
2008–2012

Research

Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world outcome
American Journal of Hematology · 2020 · First of 4 authors · 23 citations
Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment
Review · Hospital Practice · 2018 · 23 citations
Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database
Leukemia Research · 2020 · First of 9 authors · 19 citations

Mouhanna Abu Ghanimeh
12 papers · 11 as a fellow
Omar Abughanimeh
12 papers · 12 as a resident
RM
Reinhold Munker
5 papers
SA
Sakher Albadarin
4 papers · 4 as a fellow
YA
Yanal Alnimer
4 papers · 2 as a fellow
RR
Reshma Ramlal
3 papers
Fevzi Yalniz
2 papers
Gerhard Hildebrandt
2 papers
Laith Al Momani
2 papers · 2 as a resident
Mohammad Tahboub
2 papers · 2 as a resident
OY
Osama Yousef
2 papers
RA
Ranjana Arora
2 papers

Clinical trials

GM-CLAG in Relapsed/Refractory FLT3-mutated AML
Principal investigator · Withdrawn · Phase 1
Ayman H Qasrawi
2023–2032
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027